[go: up one dir, main page]

AR016011A1 - DERIVADOS DE IMIDAZOLIDINA SUSTITUíDOS, PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE MEDICAMENTOS. - Google Patents

DERIVADOS DE IMIDAZOLIDINA SUSTITUíDOS, PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE MEDICAMENTOS.

Info

Publication number
AR016011A1
AR016011A1 ARP980105821A ARP980105821A AR016011A1 AR 016011 A1 AR016011 A1 AR 016011A1 AR P980105821 A ARP980105821 A AR P980105821A AR P980105821 A ARP980105821 A AR P980105821A AR 016011 A1 AR016011 A1 AR 016011A1
Authority
AR
Argentina
Prior art keywords
alkyl
phenylene
radical
substituted
alkylene
Prior art date
Application number
ARP980105821A
Other languages
English (en)
Inventor
Wolfgang De Schmidt
Dirk Dr Seiffge
Volkmar Dr Wehner
Hans Ulrich Dr Stliz
Original Assignee
Gompel Marie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gompel Marie filed Critical Gompel Marie
Publication of AR016011A1 publication Critical patent/AR016011A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)

Abstract

Derivados de imidazolidina sustituidos de la formula I en donde W representa un radical divalente de la serie R1-A-C(R13), R1-A-C(R13)=C, de formulas II,en donde los sistemas de anillo III pueden contener dos heteroátomos, iguales o diferentes, dela serie N, O y S, pueden estar saturados o insaturados una vezo varias veces y pueden estar sustituidos con 1, 2 o 3 sustituyentes R13 iguales o diferentes y/o con uno o dos átomos de oxígeno y/o átomos de azufredoblemente unidos, y en donde Lreprese nta C(R13) o N, y en donde m1 y m2, independientemente uno de otro representan uno de los numeros 0, 1, 2, 3, 4, 5 y 6,pero la suma de m1 + m2 representa uno de los numeros 1, 2, 3, 4, 5 o 6; Y representa un grupo carbonilo, tiocarbonilo ometileno; A representa un enlacedirecto , uno de los radicales divalentes alquileno (C1-6), cicloalquileno (C3-7), fenileno, fenilen-alquilo (C1-6), fenilen-alquenilo (C2-6), o representa unradical divalente de un heterociclo de 5 miembros o 6miembros, satura do o insaturado, que puede contener uno o dos átomos de nitrogeno y que puede estarsustituido, una vez o dos veces, con alquilo (C1-C6) u oxígeno o azufre doblemente unido, estando el radical R1 en los radicales fenilenalquiloyfenilenalquenilo unido al grupo fenileno; B representa un radical divalente de la serie alquileno (C1-6), alquenileno (C2-6), fenileno, fenilen-alquilo (C1-3),alquilen (C1-3)-fenilon y alquilen (C1-3)-fenil-alquilo (C1-3), en donde el radicalalquileno (C1-6) y el radical alquenileno (C2-6) están no sustituidos oestán sustituidos con uno o varios radicales, iguales o diferentes, de la serie alquilo (C1-8), alquenilo (C2-8), alquinilo (C2-8), cicloalquilo (C3-10),cicloalquil (C3-10)-alquilo (C1-6), arilo(C6-14) eventu almente sustituido, aril (C6-14)-alquilo (C1-6) eventualmente sustituido en el radical arilo,heteroarilo eventualmente sustituido, heteroaril-alquilo (C1-6) eventualmente sustituido en el radical heteroarilo; Erepresenta tetrazolilo, (R8O)2P(O),R10O S(O)2, R9NHS(O)2, R6CO, R7CO, R10CO, HCO, R8O-CH2, R8CO-O-CH2, R8aO-CO-O-CH2 o (R8O)2P(O)-O-CH2; R representa hidrogeno, alquilo (C1-8), cicloalquilo
ARP980105821A 1997-11-19 1998-11-17 DERIVADOS DE IMIDAZOLIDINA SUSTITUíDOS, PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE MEDICAMENTOS. AR016011A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19751251A DE19751251A1 (de) 1997-11-19 1997-11-19 Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate

Publications (1)

Publication Number Publication Date
AR016011A1 true AR016011A1 (es) 2001-05-30

Family

ID=7849203

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980105821A AR016011A1 (es) 1997-11-19 1998-11-17 DERIVADOS DE IMIDAZOLIDINA SUSTITUíDOS, PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE MEDICAMENTOS.

Country Status (29)

Country Link
US (2) US6331552B1 (es)
EP (1) EP0918059B1 (es)
JP (1) JP4567821B2 (es)
KR (1) KR100738820B1 (es)
CN (1) CN1330638C (es)
AR (1) AR016011A1 (es)
AT (1) ATE243708T1 (es)
AU (1) AU755893B2 (es)
BR (1) BR9804695B1 (es)
CA (1) CA2254420C (es)
CZ (1) CZ297564B6 (es)
DE (2) DE19751251A1 (es)
DK (1) DK0918059T3 (es)
ES (1) ES2202718T3 (es)
HR (1) HRP980602B1 (es)
HU (1) HU229481B1 (es)
ID (1) ID21305A (es)
IL (1) IL127132A (es)
MY (1) MY118313A (es)
NO (1) NO325303B1 (es)
NZ (1) NZ332855A (es)
PL (1) PL194692B1 (es)
PT (1) PT918059E (es)
RU (1) RU2239641C2 (es)
SI (1) SI0918059T1 (es)
SK (1) SK284851B6 (es)
TR (1) TR199802344A2 (es)
TW (1) TWI230155B (es)
ZA (1) ZA9810543B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19821483A1 (de) * 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US6723711B2 (en) 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
US6972296B2 (en) 1999-05-07 2005-12-06 Encysive Pharmaceuticals Inc. Carboxylic acid derivatives that inhibit the binding of integrins to their receptors
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR20020067050A (ko) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 염증성, 자기면역 및 호흡기 질환의 치료에 유용한브이엘에이-4 의존성 세포 결합의 비펩티드계 억제제
GB0010105D0 (en) * 2000-04-26 2000-06-14 Ml Lab Plc Cell ablation
DE10111876A1 (de) 2001-03-10 2002-09-19 Aventis Pharma Gmbh Bis(trifluormethyl)hydantoine als Zwischenprodukte für pharmazeutische Wirkstoffe
DE10111877A1 (de) * 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US20030154499A1 (en) * 2001-06-08 2003-08-14 Monika Wasel-Nielen Mouse unable to express functional alpha-4 integrin protein, and methods for assaying compounds or agents for alpha-4 integrin protein antagonist activity and a genetic marker for evaluating efficacy of modulators of signaling activity of a VLA-4 receptor
WO2003000662A2 (en) * 2001-06-22 2003-01-03 Aventis Pharmaceuticals Inc. Chiral preparation of a diastereomeric compound
DE10134366A1 (de) * 2001-07-14 2003-01-23 Aventis Pharma Gmbh Verfahren zur Herstellung der enantiomeren Formen von 2-substituierten 2-(2,5-Dioxoimidazolidin-l-yl)-essigsäure- Derivaten
DE10137595A1 (de) * 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
ES2262996T3 (es) * 2002-01-07 2006-12-01 Eisai Co., Ltd. Deazapurinas y sus usos.
KR101011373B1 (ko) * 2002-07-11 2011-01-28 비큐론 파마슈티컬스 인코포레이티드 항균작용을 갖는 ｎ-히드록시아미드 유도체
EP1546109A4 (en) * 2002-10-04 2005-11-09 Bristol Myers Squibb Co HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND / OR TNF-ALPHA CONVERSION ENZYME (TACE)
JP4591347B2 (ja) * 2003-03-17 2010-12-01 宇部興産株式会社 ３−アミノ−３−アリールプロピオン酸ｎ−アルキルエステル及びその製造方法並びに光学活性３−アミノ−３−アリールプロピオン酸及びその対掌エステルの製造方法
CA2526730A1 (en) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives
DE102004009822A1 (de) 2004-02-28 2005-09-15 Zf Lenksysteme Gmbh Verfahren zum Betrieb eines Lenksystems mit Signalplausibilisierung
JP2009514851A (ja) 2005-11-08 2009-04-09 ランバクシー ラボラトリーズ リミテッド （３ｒ，５ｒ）−７−［２−（４−フルオロフェニル）−５−イソプロピル−３−フェニル−４−［（４−ヒドロキシメチルフェニルアミノ）カルボニル］−ピロール−１−イル］−３，５−ジヒドロキシ−ヘプタン酸ヘミカルシウム塩の製法
AU2008219007A1 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
JP5639039B2 (ja) 2008-04-11 2014-12-10 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
CN102164987B (zh) * 2008-08-22 2015-07-08 诺沃梅尔公司 用于合成聚合物的催化剂和方法
DE102009012314A1 (de) 2009-03-09 2010-09-16 Bayer Schering Pharma Aktiengesellschaft Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung
US20130337470A1 (en) 2010-10-25 2013-12-19 Biogen Idec Ma Inc. METHODS FOR DETERMINING DIFFERENCES IN ALPHA-4 INTEGRIN ACTIVITY BY CORRELATING DIFFERENCES IN sVCAM AND/OR sMadCAM LEVELS
EP3112353A1 (en) * 2015-06-30 2017-01-04 Studiengesellschaft Kohle MbH Substituted imidazolium sulfuranes and their use
EP3773573A4 (en) * 2018-04-12 2022-04-06 Morphic Therapeutic, Inc. ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4) (BETA7)
CA3121199A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Diarylhydantoin compounds and methods of use thereof
BR112022002143A2 (pt) * 2019-08-05 2022-04-19 Polyplus Transfection Composição adequada para transfectar uma molécula de ácido nucleico em uma célula, métodos para transfecção in vitro ou ex vivo de células vivas e para a produção e usos in vitro ou ex vivo da composição
RS66976B1 (sr) 2019-10-16 2025-07-31 Morphic Therapeutic Inc Inhibiranje ljudskog integrina alfa4beta7

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE235866C (es)
DE2937779A1 (de) 1979-09-19 1981-04-09 Hoechst Ag, 6000 Frankfurt Aminosaeurederivate und verfahren zu ihrer herstellung
DE3044236A1 (de) 1980-11-25 1982-06-16 Hoechst Ag, 6000 Frankfurt Aminosaeurederivate und verfahren zu ihrer herstellung
FR2487829A2 (fr) 1979-12-07 1982-02-05 Science Union & Cie Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
FR2503155A2 (fr) 1980-10-02 1982-10-08 Science Union & Cie Nouveaux imino diacides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme
US4350704A (en) 1980-10-06 1982-09-21 Warner-Lambert Company Substituted acyl derivatives of octahydro-1H-indole-2-carboxylic acids
EP0046953B1 (de) 1980-08-30 1989-12-06 Hoechst Aktiengesellschaft Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
US4344949A (en) 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
DE19575012I2 (de) 1980-10-23 2002-01-24 Schering Corp Carboxyalkyl-Dipeptide Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4374847A (en) 1980-10-27 1983-02-22 Ciba-Geigy Corporation 1-Carboxyalkanoylindoline-2-carboxylic acids
DE3226768A1 (de) 1981-11-05 1983-05-26 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
IE55867B1 (en) 1981-12-29 1991-02-14 Hoechst Ag New derivatives of bicyclic aminoacids,processes for their preparation,agents containing these compounds and their use,and new bicyclic aminoacids as intermediates and processes for their preparation
DE3210496A1 (de) 1982-03-23 1983-10-06 Hoechst Ag Neue derivate bicyclischer aminsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
DE3211397A1 (de) 1982-03-27 1983-11-10 Hoechst Ag, 6230 Frankfurt Spiro (4.(3+n))-2-aza-3-carbonsaeure-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3211676A1 (de) 1982-03-30 1983-10-06 Hoechst Ag Neue derivate von cycloalka (c) pyrrol-carbonsaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue cycloalka (c) pyrrol-carbonsaeuren als zwischenstufen und verfahren zu deren herstellung
DE3227055A1 (de) 1982-07-20 1984-01-26 Hoechst Ag, 6230 Frankfurt Neue derivate der 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie 2-aza-bicyclo(2.2.2)octan-3-carbonsaeure als zwischenstufe und verfahren zu deren herstellung
DE3242151A1 (de) 1982-11-13 1984-05-17 Hoechst Ag, 6230 Frankfurt Neue derivate tricyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung, sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung
DE3246503A1 (de) 1982-12-16 1984-06-20 Hoechst Ag, 6230 Frankfurt Derivate der cis, endo-2-azabicyclo-(5.3.0)-decan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung
DE3643012A1 (de) 1986-12-17 1988-06-30 Hoechst Ag 2,3-disubstituierte isoxazolidine, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung
DE3818850A1 (de) 1988-06-03 1989-12-07 Hoechst Ag Oligopeptide mit zyklischen prolin-analogen aminosaeuren
DE4009506A1 (de) * 1990-03-24 1991-09-26 Hoechst Ag Hydantoinderivate
DE4126277A1 (de) * 1991-08-08 1993-02-11 Cassella Ag Hydantoinderivate
RU2032672C1 (ru) * 1991-08-20 1995-04-10 Институт физико-органической химии и углехимии им.Л.М.Литвиненко АН Украины 1,3-бис-(2,3-диакрилоилоксипропил) -5,5-диметил-2,4-имидазолидиндион в качестве модификатора фотополимеризующихся акрилатных композиций
CA2127462C (en) * 1992-01-13 1999-03-23 Roy R. Lobb Treatment for asthma
HK1007683A1 (en) * 1992-02-12 1999-04-23 Biogen, Inc. Treatment for inflammatory bowel disease
DE4207254A1 (de) * 1992-03-07 1993-09-09 Cassella Ag 4-oxo-2-thioxoimidazolidin-derivate
DE4213634A1 (de) * 1992-04-24 1993-10-28 Cassella Ag 2,4-Dioxo-imidazolidin-Derivate
DE4224414A1 (de) * 1992-07-24 1994-01-27 Cassella Ag Phenylimidazolidin-derivate, ihre Herstellung und ihre Verwendung
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
CA2153228A1 (en) 1993-01-08 1994-07-21 Shiu-Lan Ng Chiang Peptide inhibitors of cell adhesion
ATE182625T1 (de) 1993-01-12 1999-08-15 Biogen Inc Rekombinante anti-vla4 antikörpermoleküle
JP3593343B2 (ja) 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
DE4308034A1 (de) 1993-03-13 1994-09-15 Cassella Ag Neue Heterocyclen, ihre Herstellung und ihre Verwendung
DE4427979A1 (de) * 1993-11-15 1996-02-15 Cassella Ag Substituierte 5-Ring-Heterocyclen, ihre Herstellung und ihre Verwendung
WO1995015973A1 (en) 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
WO1995019790A1 (en) 1994-01-25 1995-07-27 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule vla-4
AU2958195A (en) * 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
DE19515177A1 (de) 1995-04-28 1996-10-31 Cassella Ag Hydantoinderivate als Zwischenprodukte für pharmazeutische Wirkstoffe
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
ATE212990T1 (de) * 1996-03-20 2002-02-15 Hoechst Ag Inhibitoren der knochenresorption und vitronectinrezeptor-antagonisten
KR20040084945A (ko) 1996-07-25 2004-10-06 바이오겐 아이덱 엠에이 인코포레이티드 세포 유착 억제제
DE19647380A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag 5-Ring-Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647382A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19647381A1 (de) * 1996-11-15 1998-05-20 Hoechst Ag Neue Heterocyclen als Inhibitoren der Leukozytenadhäsion und VLA-4-Antagonisten
DE19648053C1 (de) 1996-11-20 1998-03-12 Siemens Ag Elektromagnetisches Schaltgerät
WO1998042656A1 (en) 1997-03-21 1998-10-01 Cytel Corporation Novel compounds

Also Published As

Publication number Publication date
AU755893B2 (en) 2003-01-02
JPH11246531A (ja) 1999-09-14
HK1020949A1 (en) 2000-05-26
CA2254420A1 (en) 1999-05-19
MY118313A (en) 2004-09-30
NO325303B1 (no) 2008-03-25
HUP9802653A2 (hu) 1999-09-28
SK158098A3 (en) 1999-06-11
DE19751251A1 (de) 1999-05-20
KR100738820B1 (ko) 2008-02-20
EP0918059A1 (de) 1999-05-26
US6521654B2 (en) 2003-02-18
AU9242198A (en) 1999-06-10
PL194692B1 (pl) 2007-06-29
RU2239641C2 (ru) 2004-11-10
HRP980602B1 (en) 2006-07-31
HU229481B1 (hu) 2014-01-28
ID21305A (id) 1999-05-20
CZ297564B6 (cs) 2007-02-07
HRP980602A2 (en) 1999-08-31
ZA9810543B (en) 1999-05-19
JP4567821B2 (ja) 2010-10-20
DK0918059T3 (da) 2003-10-13
BR9804695B1 (pt) 2010-11-30
HUP9802653A3 (en) 2000-09-28
CZ372698A3 (cs) 1999-06-16
SK284851B6 (sk) 2006-01-05
IL127132A (en) 2005-03-20
ES2202718T3 (es) 2004-04-01
PT918059E (pt) 2003-11-28
CN1225360A (zh) 1999-08-11
ATE243708T1 (de) 2003-07-15
DE59808804D1 (de) 2003-07-31
US6331552B1 (en) 2001-12-18
NO985368D0 (no) 1998-11-18
KR19990045365A (ko) 1999-06-25
SI0918059T1 (en) 2003-12-31
EP0918059B1 (de) 2003-06-25
PL329790A1 (en) 1999-05-24
US20020143043A1 (en) 2002-10-03
TR199802344A2 (xx) 1999-06-21
NZ332855A (en) 2000-06-23
BR9804695A (pt) 2001-05-22
TWI230155B (en) 2005-04-01
HU9802653D0 (en) 1999-01-28
NO985368L (no) 1999-05-20
CN1330638C (zh) 2007-08-08
CA2254420C (en) 2009-05-26
IL127132A0 (en) 1999-09-22

Similar Documents

Publication Publication Date Title
AR016011A1 (es) DERIVADOS DE IMIDAZOLIDINA SUSTITUíDOS, PROCEDIMIENTO PARA SU PREPARACIoN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y EL USO DE LOS MISMOS PARA LA MANUFACTURA DE MEDICAMENTOS.
MA27664A1 (fr) Acides gras a chaine moyenne, glycerides et analogues utilises en tant que stimulateurs de l'erythropoiese
EA200200299A1 (ru) НОВЫЕ α-АМИНОКИСЛОТНЫЕ СУЛЬФОНИЛЬНЫЕ СОЕДИНЕНИЯ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ИХ СОДЕРЖАЩИЕ
TR200602858T2 (tr) Bitki zararlılarının kontrol edilmesi için bileşimler.
CY1108445T1 (el) Νεα μεθοδος συνθεσης και νεα κρυσταλλικη μορφη της αγομελατινης καθως και φαρμακευτικες συνθεσεις που την περιεχουν
EP1302470A4 (en) INHIBITORS OF PLATES RICH IN LIPID
AR002277A1 (es) Compuestos utiles como inhibidores de la trombina, composiciones farmaceuticas que los contienen y sustancias peptidicas y peptidomimeticasinhibidoras de la serinproteasa.
DE69902875D1 (de) Tts enthaltend ein antioxidans
AR024364A1 (es) Una composicion cosmetica para el adelgazamiento a base l-arginina, de un analogo de l-arginina, o de uno de sus derivados, que se administra por viatopica
RU2001118831A (ru) Макролиды, обладающие противовоспалительной активностью
ATE206116T1 (de) 6-carboxamido-dihydropyran-derivate
ECSP034838A (es) Inmunoconjugados del anticuerpo cd44 citotoxico
MX9303123A (es) Ciclopentano-y-penteno-beta-aminoacidos, procedimiento para su preparacion y medicamentos que los contienen.
NO991233L (no) Nye trisykliske piperidinylforbindelser anvendelige som inhibitorer av farnesylproteintransferase
KR950032257A (ko) 종양 간전이 억제제
AR029618A1 (es) Compuestos de amida , procedimientos para prepararlos, las composiciones farmaceuticas que los contienen y el uso de dichos compuestos para la fabricacion de medicamentos
AR018619A1 (es) Derivados de 8-fenilxantina utiles como inhibidores de fosfoestearasa gmp ciclica (pdes), preparacion, composiciones farmaceuticas formuladas con dichosderivados y uso de dichos derivados para la fabricacion de medicamentos
CO5650220A2 (es) Composicion dental antiplaca de confiteria que contiene un compuesto de ester antibacteriano
BR9904951A (pt) Compostos cìclicos tendo uma cadeia cicloalquileno, processo para sua preparação e composições farmacêuticas contendo os mesmos
AR004896A1 (es) Derivados de pirazoles acidos, procedimiento de preparación, medicamentos y las composiciones farmacueitcas que los contienen, compuestos para suexclusivo uso en dicho procedimiento y utilizacion de dichos derivados para preparar composiciones farmaceuticas.
CO4980875A1 (es) Nuevos derivados de la equinocandina, su procedimiento de preparacion y su aplicacion como fungicidas
TR200801031T2 (tr) Bitki zararlılarının kontrol edilmesi için bileşimler.
KR870000298A (ko) 심장혈관의 병 치료용 1,4-디하이드로피리딘 유도체의 제법
CO4940470A1 (es) Compuestos 5,6,7-trisustituidos-4-aminopirido[2,3-d]pirimi- dina
CO4940439A1 (es) COMPUESTOS 4-AMINO-6,7-DISUSTITUIDOS-PIRIDO-[2,3-d] PIRIMI- DINA

Legal Events

Date Code Title Description
FG Grant, registration